Australian biopharmaceutical company Immuron has acquired intellectual property related to oral immunotherapies from Hadasit, the technology-transfer arm of Hadassah University Medical Center in Israel, the organizations said this week.

The deal establishes Hadasit as the largest shareholder in Immuron with a 19.99 percent stake, Hadasit and Immuron said.

The IP relates to the concept of treating automimmune and chronic disease with orally delivered polyclonal antibodies, developed by Yaron Ilan and colleagues at Hadassah.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."